---
title: "Spyre Therapeutics CFO Scott Burrows disposes of common shares worth $1.31 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291018748.md"
description: "Spyre Therapeutics CFO Scott Burrows exercised options for 15,000 shares at $14.50 and sold them the same day at ~$87.13, totaling $1.31 million. Post-transaction, he holds 97,994 direct shares and beneficial ownership of 359,857 stock options."
datetime: "2026-06-27T01:32:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291018748.md)
  - [en](https://longbridge.com/en/news/291018748.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291018748.md)
---

# Spyre Therapeutics CFO Scott Burrows disposes of common shares worth $1.31 million

-   Spyre Therapeutics CFO Scott L. Burrows exercised stock options, acquiring 15,000 common shares at $14.5 on June 25. \* Burrows sold 15,000 shares the same day for about $87.13 a share, leaving direct holdings of 97,994 shares. \* He reported beneficial ownership of 359,857 stock options following the transaction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001853327-26-000008), on June 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [SYRE.US](https://longbridge.com/en/quote/SYRE.US.md)

## Related News & Research

- [Spyre Therapeutics grants inducement equity awards to four new hires at $94.93 strike price](https://longbridge.com/en/news/295272795.md)
- [Spyre Therapeutics Q2 loss narrower than expected; sees trial readouts in 2026](https://longbridge.com/en/news/294864706.md)
- [178,389 Shares in Spyre Therapeutics, Inc. $SYRE Acquired by First Trust Advisors LP](https://longbridge.com/en/news/294576561.md)
- [Spyre Therapeutics: Merck TL1A Readthrough Supports Multi-Disease Opportunity, Solid Cash Runway, and Unchanged $119 Buy Target](https://longbridge.com/en/news/294870016.md)
- [MTRN: Q2 2026 net sales surged 42% and net income rose 54%, led by Electronic Materials growth](https://longbridge.com/en/news/295002284.md)